Aegerion Pharmaceuticals, Inc. Comments on Standard Review Classification for Lomitapide NDA

Published: Mar 08, 2012

CAMBRIDGE, Mass., March 8, 2012 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), an emerging biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat severe lipid disorders, today commented on U.S. Food and Drug Administration (FDA)'s standard review classification of Aegerion's New Drug Application (NDA) for its lead investigational therapeutic, lomitapide.

Back to news